Bioventus (NYSE:BVS) Releases FY 2025 Earnings Guidance

Bioventus (NYSE:BVS) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.550. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $554.8 million.

Bioventus Trading Up 18.4 %

Bioventus stock opened at $10.37 on Tuesday. The business’s fifty day simple moving average is $10.12 and its two-hundred day simple moving average is $11.01. Bioventus has a 12 month low of $3.90 and a 12 month high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company has a market capitalization of $841.58 million, a price-to-earnings ratio of -17.00 and a beta of 0.86.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Insider Transactions at Bioventus

In other Bioventus news, CEO Robert E. Claypoole sold 28,786 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the completion of the sale, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 52,932 shares of company stock worth $512,511 in the last three months. Insiders own 32.90% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.